Literature DB >> 24158270

Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.

Gauthier Remiche1, Dario Ronchi, Francesca Magri, Costanza Lamperti, Andreina Bordoni, Maurizio Moggio, Nereo Bresolin, Giacomo P Comi.   

Abstract

Glycogen storage disease type II (GSDII) is a lysosomal storage disorder caused by acid alpha-1,4-glucosidase deficiency and associated with recessive mutations in its coding gene GAA. Few studies have provided so far a detailed phenotypical characterization in late onset GSDII (LO-GSDII) patients. Genotype-phenotype correlation has been previously attempted with controversial results. We aim to provide an in-depth description of a cohort (n = 36) of LO-GSDII patients coming from the north of Italy and compare our population's findings to the literature. We performed a clinical record-based retrospective and prospective study of our patients. LO-GSDII in our cohort covers a large variability of phenotype including subtle clinical presentation and did not differ significantly from previous data. In all patients, molecular analysis disclosed GAA mutations, five of them being novel. To assess potential genotype-phenotype correlations we divided IVS1-32-13T>G heterozygous patients into two groups following the severity of the mutations on the second allele. Our patients harbouring "severe" mutations (n = 21) presented a strong tendency to have more severe phenotypes and more disability, more severe phenotypes and more disability, higher prevalence of assisted ventilation and a shorter time of evolution to show it. The determination of prognostic factors is mandatory in order to refine the accuracy of prognostic information, to develop follow-up strategy and, more importantly, to improve the decision algorithm for enzyme replacement therapy administration. The demonstration of genotype-phenotype correlations could help to reach this objective. Clinical assessment homogeneity is required to overcome limitations due to the lack of power of most studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24158270     DOI: 10.1007/s00415-013-7137-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  57 in total

1.  Muscle MRI in adult-onset acid maltase deficiency.

Authors:  Anna Pichiecchio; Carla Uggetti; Sabrina Ravaglia; Maria Grazia Egitto; Miriam Rossi; Giorgio Sandrini; Cesare Danesino
Journal:  Neuromuscul Disord       Date:  2004-01       Impact factor: 4.296

2.  Seven cases of Pompe disease from Greece.

Authors:  M Kroos; P Manta; I Mavridou; F Muntoni; D Halley; R Van der Helm; D Zaifeiriou; A Van der Ploeg; A Reuser; H Michelakakis
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

3.  Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations.

Authors:  Rachel E Palmer; Hernan M Amartino; Gabriela Niizawa; Mariana Blanco; Robert J Pomponio; Nestor A Chamoles
Journal:  Neuromuscul Disord       Date:  2006-10-23       Impact factor: 4.296

Review 4.  Diagnosis of glycogenosis type II.

Authors:  B Bembi; E Cerini; C Danesino; M A Donati; S Gasperini; L Morandi; O Musumeci; G Parenti; S Ravaglia; F Seidita; A Toscano; A Vianello
Journal:  Neurology       Date:  2008-12-02       Impact factor: 9.910

5.  Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease.

Authors:  F Martiniuk; A Chen; A Mack; E Arvanitopoulos; Y Chen; W N Rom; W J Codd; B Hanna; P Alcabes; N Raben; P Plotz
Journal:  Am J Med Genet       Date:  1998-08-27

Review 6.  The natural course of non-classic Pompe's disease; a review of 225 published cases.

Authors:  Léon P F Winkel; Marloes L C Hagemans; Pieter A van Doorn; M Christa B Loonen; Wim J C Hop; Arnold J J Reuser; Ans T van der Ploeg
Journal:  J Neurol       Date:  2005-08       Impact factor: 4.849

7.  Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II.

Authors:  Bruno Bembi; Federica Edith Pisa; Marco Confalonieri; Giovanni Ciana; Agata Fiumara; Rossella Parini; Miriam Rigoldi; Arrigo Moglia; Alfredo Costa; Annalisa Carlucci; Cesare Danesino; Maria Gabriela Pittis; Andrea Dardis; Sabrina Ravaglia
Journal:  J Inherit Metab Dis       Date:  2010-09-14       Impact factor: 4.982

Review 8.  Pompe's disease.

Authors:  Ans T van der Ploeg; Arnold J J Reuser
Journal:  Lancet       Date:  2008-10-11       Impact factor: 79.321

9.  The angiotensin-converting enzyme insertion/deletion polymorphism modifies the clinical outcome in patients with Pompe disease.

Authors:  Paola de Filippi; Sabrina Ravaglia; Bruno Bembi; Alfredo Costa; Arrigo Moglia; Giovanni Piccolo; Alessandra Repetto; Andrea Dardis; Giuseppe Greco; Giovanni Ciana; Francesco Canevari; Cesare Danesino
Journal:  Genet Med       Date:  2010-04       Impact factor: 8.822

10.  A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations.

Authors:  Andreas Herzog; Ralf Hartung; Arnold J J Reuser; Pia Hermanns; Heiko Runz; Nesrin Karabul; Seyfullah Gökce; Joachim Pohlenz; Christoph Kampmann; Christina Lampe; Michael Beck; Eugen Mengel
Journal:  Orphanet J Rare Dis       Date:  2012-06-07       Impact factor: 4.123

View more
  8 in total

1.  Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

Authors:  Claudio Semplicini; Pascaline Letard; Marie De Antonio; Nadjib Taouagh; Barbara Perniconi; Françoise Bouhour; Andoni Echaniz-Laguna; David Orlikowski; Sabrina Sacconi; Emmanuelle Salort-Campana; Guilhem Solé; Fabien Zagnoli; Dalil Hamroun; Roseline Froissart; Catherine Caillaud; Pascal Laforêt
Journal:  J Inherit Metab Dis       Date:  2018-08-28       Impact factor: 4.982

2.  Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.

Authors:  Federica Montagnese; E Barca; O Musumeci; S Mondello; A Migliorato; A Ciranni; C Rodolico; P De Filippi; C Danesino; A Toscano
Journal:  J Neurol       Date:  2015-02-12       Impact factor: 4.849

3.  Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent.

Authors:  Samya Chakravorty; Babi Ramesh Reddy Nallamilli; Satish Vasant Khadilkar; Madhu Bala Singla; Ashish Bhutada; Rashna Dastur; Pradnya Satish Gaitonde; Laura E Rufibach; Logan Gloster; Madhuri Hegde
Journal:  Front Neurol       Date:  2020-11-05       Impact factor: 4.086

4.  Variable clinical features and genotype-phenotype correlations in 18 patients with late-onset Pompe disease.

Authors:  Jousef Alandy-Dy; Marie Wencel; Kathy Hall; Julie Simon; Yanjun Chen; Erik Valenti; Jade Yang; Deeksha Bali; Anita Lakatos; Namita Goyal; Tahseen Mozaffar; Virginia Kimonis
Journal:  Ann Transl Med       Date:  2019-07

5.  Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation.

Authors:  Xiao Liu; Zhaoxia Wang; Weina Jin; He Lv; Wei Zhang; Chengli Que; Yu Huang; Yun Yuan
Journal:  BMC Med Genet       Date:  2014-12-20       Impact factor: 2.103

Review 6.  Glycogen metabolism in humans.

Authors:  María M Adeva-Andany; Manuel González-Lucán; Cristóbal Donapetry-García; Carlos Fernández-Fernández; Eva Ameneiros-Rodríguez
Journal:  BBA Clin       Date:  2016-02-27

7.  Comprehensive approach to weaning in difficult-to-wean infantile and juvenile-onset glycogen-storage disease type II patients: a case series.

Authors:  Lingling Xu; Hongjun Ba; Yuxin Pei; Xueqiong Huang; Yujian Liang; Lidan Zhang; Huimin Huang; Cheng Zhang; Wen Tang
Journal:  Ital J Pediatr       Date:  2019-08-22       Impact factor: 2.638

8.  Genotype-phenotype correlation in Pompe disease, a step forward.

Authors:  Paola De Filippi; Kolsoum Saeidi; Sabrina Ravaglia; Andrea Dardis; Corrado Angelini; Tiziana Mongini; Lucia Morandi; Maurizio Moggio; Antonio Di Muzio; Massimiliano Filosto; Bruno Bembi; Fabio Giannini; Giovanni Marrosu; Miriam Rigoldi; Paola Tonin; Serenella Servidei; Gabriele Siciliano; Annalisa Carlucci; Claudia Scotti; Mario Comelli; Antonio Toscano; Cesare Danesino
Journal:  Orphanet J Rare Dis       Date:  2014-08-08       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.